c-Kit
SCFR; CD117

c-Kit (Mast/stem cell growth factor receptor, SCFR or CD117) is a protein that in humans is encoded by the KIT gene. c-Kit (CD117) is an important cell surface marker used to identify certain types of hematopoietic (blood) progenitors in the bone marrow. c-Kit is a cytokine receptor expressed on the surface of hematopoietic stem cells as well as other cell types. Altered forms of this receptor may be associated with some types of cancer. c-Kit is a receptor tyrosine kinase type III, which binds to stem cell factor. When c-Kit binds to stem cell factor (SCF) it forms a dimer that activates its intrinsic tyrosine kinase activity, that in turn phosphorylates and activates signal transduction molecules that propagate the signal in the cell. Signalling through c-Kit plays a role in cell survival, proliferation, and differentiation.
c-Kit Inhibitors

AC710

AC710 is a potent PDGFR inhibitor with $K_c$ of 0.6, 1.57, 1, 1.3, 1.0 nM for FLT3, CSF1R, KIT, PDGFRα and PDGFRβ, respectively.

Purity: 98.03%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Amuvatinib hydrochloride (MP470 hydrochloride; HPK 56 hydrochloride)

Amuvatinib hydrochloride (MP470 hydrochloride) is an orally bioavailable multi-targeted tyrosine kinase inhibitor with potent activity against mutant c-Kit, PDGFRα, Flt3, c-Met and c-Ret.

Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

Apatinib free base (YN968D1 free base)

Apatinib free base (YN968D1 free base) is an orally bioavailable tyrosine kinase inhibitor, which selectively targets VEGFR-2 with an $IC_{50}$ of 1 nM. Apatinib (YN968D1) also potently suppresses the activities of Ret, c-Kit and c-Src with $IC_{50}$s of 13, 429 and 530 nM, respectively.

Purity: 99.93%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Avapritinib (BLU-285)

Avapritinib (BLU-285) is a highly potent, selective, and orally bioavailable KIT and PDGFRα activation loop mutant inhibitors with $IC_{50}$ of 0.27 and 0.24 nM for KIT D816V and PDGFRα D842V, respectively.

Purity: >98.0%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Apatinib (YN968D1)

Apatinib (YN968D1) is an orally bioavailable tyrosine kinase inhibitor, which selectively targets VEGFR2 with an $IC_{50}$ of 1 nM. Apatinib (YN968D1) also potently suppresses the activities of Ret, c-Kit and c-Src with $IC_{50}$s of 13, 429 and 530 nM, respectively.

Purity: 99.93%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

AZD2932

AZD2932 is a potent and multi-targeted kinase inhibitor VEGFR2, PDGFRβ, Flt-3 and c-Kit with $IC_{50}$s of 8.4, 7 and 9 nM in cell assay, respectively.

Purity: 98.12%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

AZD3229 Tosylate

AZD3229 Tosylate is a potent pan-KIT mutant inhibitor for the treatment of gastrointestinal stromal tumors.

Purity: 98.54%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg
c-Kit-IN-1

Cat. No.: HY-15240

c-Kit-IN-1 is a potent inhibitor of c-Kit and c-Met with IC\textsubscript{50}s of <200 nM.

Purity: 98.46%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

---

c-Kit-IN-2

Cat. No.: HY-128602

c-Kit-IN-2 is a c-KIT inhibitor with an IC\textsubscript{50} of 82 nM, shows superior antiproliferative activities against all the three GIST cell lines, GIST882, GIST430, and GIST48, with IC\textsubscript{50}s of 3, 1, and 2 nM, respectively.

Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

---

c-Kit-IN-3

Cat. No.: HY-128704

c-Kit-IN-3 (Compound 18) is a potent and selective c-KIT kinase inhibitor with an IC\textsubscript{50} of 4 nM, 8 nM for c-KIT wt and c-KIT T670I, respectively.

Purity: 99.07%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

---

c-Kit-IN-3 D-tartrate

Cat. No.: HY-128704A5

c-Kit-IN-3 (D-tartrate) (Compound 18) is a potent and selective c-KIT kinase inhibitor with an IC\textsubscript{50} of 4 nM and a broad spectrum of drug-resistant mutants (IC\textsubscript{50} of 8 nM...)

Purity: >98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

---

c-Kit-IN-3 hydrochloride

Cat. No.: HY-128704A1

c-Kit-IN-3 hydrochloride (Compound 18) is a potent c-KIT kinase inhibitor, which is potent and selective against BaF3-tel-c-KIT (IC\textsubscript{50} of 4 nM) and a broad spectrum of drug-resistant mutants (IC\textsubscript{50} of 8 nM for BaF3-tel-c-KIT-T670I)...

Purity: >98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

---

c-Kit-IN-3 L-tartrate

Cat. No.: HY-128704A6

c-Kit-IN-3 L-tartrate (Compound 18) is a potent and selective c-KIT kinase inhibitor with an IC\textsubscript{50} of 4 nM, 8 nM for c-KIT wt and c-KIT T670I, respectively.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

---

c-Kit-IN-3 maleate

Cat. No.: HY-128704A4

c-Kit-IN-3 maleate (Compound 18) is a potent and selective c-KIT kinase inhibitor with an IC\textsubscript{50} of 4 nM. c-Kit-IN-3 maleate displays great potencies against c-KIT kinase and a broad spectrum of drug-resistant mutants in the biochemical assay. c-Kit-IN-3 maleate has improved bioavailability.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

---

c-Kit-IN-3 tartrate

Cat. No.: HY-128704A7

c-Kit-IN-3 tartrate (Compound 18) is a potent c-KIT kinase inhibitor, which is potent and selective against BaF3-tel-c-KIT (IC\textsubscript{50} of 4 nM) and a broad spectrum of drug-resistant mutants (IC\textsubscript{50} of 8 nM...)

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

---

Cabozantinib

(XL184; BMS-907351)

Cat. No.: HY-13016

Cabozantinib is a potent multiple receptor tyrosine kinases (RTKs) inhibitor that inhibits VEGFR2, c-Met, Kit, Axl and Flt3 with IC\textsubscript{50}s of 0.035, 1.3, 4.6, 7 and 11.3 nM, respectively.

Purity: 99.85%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

---

CHMFL-ABL/KIT-155

(CHMFL-ABL-KIT-155)

Cat. No.: HY-101034

CHMFL-ABL/KIT-155 (CHMFL-ABL-KIT-155; compound 34) is a highly potent and orally active type II ABL/c-KIT dual kinase inhibitor (IC\textsubscript{50}s of 46 nM and 75 nM, respectively), and it also presents significant inhibitory activities to BLK (IC\textsubscript{50}=81 nM), CSF1R (IC\textsubscript{50}=227 nM), DDR1 (IC\textsubscript{50}=116 nM)... Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg
CHMFL-KIT-033

Cat. No.: HY-128589

CHMFL-KIT-033 is a potent and selective inhibitor of c-KIT T670I mutant for gastrointestinal stromal tumors (GISTs), with an IC₅₀ of 0.045 μM.

Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

Flumatinib

(HHGV678)

Cat. No.: HY-13904

Flumatinib (HHGV678) is a multi-kinase inhibitor with IC₅₀ Values of 1.2 nM, 307.6 nM and 2662 nM for c-Abl, PDGFRβ and c-Kit respectively.

Purity: 99.94%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Imatinib

(STI571; CGP-57148B)

Cat. No.: HY-15463

Imatinib (STI571) is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity.

Purity: 99.80%
Clinical Data: Launched
Size: 10 mM × 1 mL, 200 mg, 500 mg, 1 g, 5 g

Imatinib D8

(STI571 D8; CGP-57148B D8)

Cat. No.: HY-154635

Imatinib D8 (STI571 D8) is a deuterium labeled Imatinib (STI571). Imatinib is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

ISCK03

Cat. No.: HY-101443

ISCK03 is a specific SCF/c-Kit inhibitor.

Purity: 99.27%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Dovitinib

(TKI258; CHIR-258)

Cat. No.: HY-50905

Dovitinib (TKI258; CHIR-258) is a multi-targeted tyrosine kinase inhibitor with IC₅₀ of 1, 2, 8/9, 10/13/8, 27/210 nM for FLT3, c-Kit, FGFR1/3, VEGFR2/3 and PDGFRα/β, respectively.

Purity: 97.18%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg

Flumatinib mesylate

(HHGV678 mesylate)

Cat. No.: HY-13905

Flumatinib mesylate (HH-GV-678 mesylate), a derivative of imatinib, is a multi-kinase inhibitor with IC₅₀ Values of 1.2 nM, 307.6 nM and 2662 nM for c-Abl, PDGFRβ and c-Kit respectively.

Purity: 99.97%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 500 mg

Imatinib D4

(STI571 D4; CGP-57148B D4)

Cat. No.: HY-1546351

Imatinib D4 (STI571 D4) is a deuterium labeled Imatinib (STI571). Imatinib is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Imatinib Mesylate

(STI571 Mesylate; CGP-57148B Mesylate)

Cat. No.: HY-50946

Imatinib Mesylate (STI571 Mesylate) is a tyrosine kinases inhibitor that inhibits c-Kit, Bcr-Ab1, and PDGFR (IC₅₀=100 nM) tyrosine kinases.

Purity: 99.91%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 200 mg, 500 mg, 1 g, 5 g

Ki20227

Cat. No.: HY-10408

Ki20227 is an orally active and highly selective c-Fms tyrosine kinase (CSF1R) inhibitor with IC₅₀ of 2 nM, 12 nM, 451 and 217 nM for CSF1R, VEGFR2 (vascular endothelial growth factor receptor-2), c-Kit (stem cell factor receptor) and PDGFRβ (platelet-derived growth factor...

Purity: 99.17%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg
Lenvatinib (E7080) is an oral, multi-targeted tyrosine kinase inhibitor that inhibits VEGFR1, VEGFR2, FGFFR3, PDGFRα/β, c-Kit, FGRF1, and c-Fms with IC_{50}s of 10, 30, 47, 84, 74, 140 and 146 nM, respectively.

Purity: 99.64%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Linifanib (ABT-869; AL-39324)

Linifanib (ABT-869) is a potent and orally active multi-target inhibitor of VEGFR and PDGFR family with IC_{50}s of 4, 3, 66, and 4 nM for KDR, FLT1, PDGFRβ, and FLT3, respectively. Linifanib (ABT-869) shows promiment antitumor activity.

Purity: 99.60%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Masitinib mesylate (AB-1010 mesylate)

Masitinib mesylate (AB-1010) is a potent, orally bioavailable, and selective inhibitor of c-Kit [IC_{50}=200 nM for human recombinant c-Kit]. It also inhibits PDGFRα/β [IC_{50}s=540/800 nM], Lyn [IC_{50}=510 nM for LynB], Lck, and, to a lesser extent, FGRF3 and FAK.

Purity: 99.94%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg

Motesanib (AMG 706)

Motesanib is a potent ATP-competitive inhibitor of VEGFR1/2/3 C>B with IC_{50}s of 2 nM/3 nM/6 nM, respectively, and has similar activity against Kit, and is approximately 10-fold more selective for VEGFR than PDGFR and Ret.

Purity: 99.75%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

OSI-930

OSI-930 is a potent inhibitor of Kit, KDR and CSF-1R with IC_{50} of 80 nM, 9 nM and 15 nM, respectively, also potent to Flt-1, c-Raf and Lck and low activity against PDGFRα/β, Flt-3 and Abl.

Purity: 97.23%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Pazopanib Hydrochloride (GW786034 Hydrochloride)

Pazopanib Hydrochloride (GW786034 Hydrochloride) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRα/β, c-Kit, FGRF1, and c-Fms with an IC_{50} of 10, 30, 47, 84, 74, 140 and 146 nM, respectively.

Purity: 99.83%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg
Pexidartinib (PLX-3397) is a potent, orally active, selective, and ATP-competitive colony stimulating factor 1 receptor (CSF1R or M-CSFR) and c-Kit inhibitor, with IC50 of 20 and 10 nM, respectively.

Purity: 99.64%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

**Pexidartinib hydrochloride (PLX-3397 hydrochloride)**

Pexidartinib hydrochloride (PLX-3397 hydrochloride) is a potent, orally active, selective, and ATP-competitive colony stimulating factor 1 receptor (CSF1R or M-CSFR) and c-Kit inhibitor, with IC50 of 20 and 10 nM, respectively.

Purity: 99.95%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

**PLX647**

PLX647 is a highly specific dual FMS/KIT kinase inhibitor with IC50 of 28/16 nM respectively.

Purity: 98.20%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

**Ripretinib (DCC-2618)**

Ripretinib (DCC-2618) is an orally bioavailable, selective KIT and PDGFRα switch-control inhibitor.

Purity: 99.46%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

**Sitravatinib (MGCD516; MG-516)**

Sitravatinib (MGCD516) is an orally bioavailable receptor tyrosine kinase (RTK) inhibitor with IC50 of 1.5 nM, 2 nM, 2 nM, 5 nM, 6 nM, 6 nM, 8 nM, 0.5 nM, 29 nM, 5 nM, and 9 nM for Axl, MER, VEGFR3, VEGFR2, VEGFR1, KIT, FLT3, DDR2, DDR1, TRKA, TRKB, respectively.

Purity: 99.85%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

**Sitravatinib malate (MGCD516 maleate; MG-516 maleate)**

Sitravatinib malate (MGCD516 maleate) is an orally bioavailable receptor tyrosine kinase (RTK) inhibitor with IC50 of 1.5 nM, 2 nM, 2 nM, 5 nM, 6 nM, 6 nM, 8 nM, 0.5 nM, 29 nM, 5 nM, and 9 nM for Axl, MER, VEGFR3, VEGFR2, VEGFR1, KIT, FLT3, DDR2, DDR1, TRKA, TRKB, respectively.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

**SU14813**

SU14813 is a multi-targeted receptor tyrosine kinases inhibitor with IC50 of 50, 2, 4, 15 nM for VEGFR2, VEGFR1, PDGFRβ and KIT.

Purity: 98.90%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

**SU14813 maleate (MGDS1 maleate; MG-516 maleate)**

SU14813 maleate is a multi-targeted receptor tyrosine kinases inhibitor with IC50 of 50, 2, 4, 15 nM for VEGFR2, VEGFR1, PDGFRβ and KIT.

Purity: 99.95%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

**Tandutinib (MLN518; CT53518)**

Tandutinib (MLN518) is a potent and selective inhibitor of the FLT3 with an IC50 of 0.22 μM, and also inhibits c-Kit and PDGFR with IC50 of 0.17 μM and 0.20 μM, respectively. Tandutinib can be used to treat acute myelogenous leukemia (AML).

Purity: 99.81%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 50 mg, 100 mg

**Tandutinib hydrochloride (MLN518 hydrochloride; CT53518 hydrochloride)**

Tandutinib hydrochloride (MLN518 hydrochloride) is a potent and selective inhibitor of the FLT3 with an IC50 of 0.22 μM, and also inhibits c-Kit and PDGFR with IC50 of 0.17 μM and 0.20 μM, respectively.

Purity: 98.84%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 50 mg, 100 mg
| **Telatinib**  
| (Bay 57-9352)  
| Cat. No.: HY-10527  
| Telatinib (Bay 57-9352) is an orally active, small molecule inhibitor of VEGFR2, VEGFR3, PDGFrα, and c-Kit with IC\(_{50}\)s of 6, 4, 15 and 1 nM, respectively.  
| **Purity:** 99.49%  
| **Clinical Data:** Phase 2  
| **Size:** 10 mM x 1 mL, 5 mg, 10 mg, 50 mg, 100 mg  
| **Toceranib**  
| (SU11654; PHA 291639E)  
| Cat. No.: HY-10330  
| Toceranib phosphate (SU11654 phosphate) is an orally active receptor tyrosine kinase (RTK) inhibitor, and it potently inhibits PDGFR, VEGFR, and Kit with \(K_i\)s of 5 and 6 nM for PDGFRβ and Flk-1/KDR, respectively.  
| **Purity:** 96.50%  
| **Clinical Data:** Launched  
| **Size:** 10 mg, 50 mg  
| **Toceranib phosphate**  
| (SU11654 phosphate; PHA 291639E phosphate)  
| Cat. No.: HY-10330A  
| Toceranib phosphate (SU11654 phosphate) is an orally active receptor tyrosine kinase (RTK) inhibitor, and it potently inhibits PDGFR, VEGFR, and Kit with \(K_i\)s of 5 and 6 nM for PDGFRβ and Flk-1/KDR, respectively.  
| **Purity:** 98.43%  
| **Clinical Data:** Launched  
| **Size:** 10 mg, 50 mg  

www.MedChemExpress.com